CL2024001071A1 - Métodos para efectuar un cambio hemodinámico administrando un anticuerpo anti-npr1. - Google Patents

Métodos para efectuar un cambio hemodinámico administrando un anticuerpo anti-npr1.

Info

Publication number
CL2024001071A1
CL2024001071A1 CL2024001071A CL2024001071A CL2024001071A1 CL 2024001071 A1 CL2024001071 A1 CL 2024001071A1 CL 2024001071 A CL2024001071 A CL 2024001071A CL 2024001071 A CL2024001071 A CL 2024001071A CL 2024001071 A1 CL2024001071 A1 CL 2024001071A1
Authority
CL
Chile
Prior art keywords
methods
effecting
administering
npr1
hemodynamic change
Prior art date
Application number
CL2024001071A
Other languages
English (en)
Spanish (es)
Inventor
Dunn Michael
Kithcart Aaron
Adam Olenchock Benjamin
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2024001071A1 publication Critical patent/CL2024001071A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2024001071A 2021-10-11 2024-04-10 Métodos para efectuar un cambio hemodinámico administrando un anticuerpo anti-npr1. CL2024001071A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163254447P 2021-10-11 2021-10-11

Publications (1)

Publication Number Publication Date
CL2024001071A1 true CL2024001071A1 (es) 2024-12-06

Family

ID=84045029

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024001071A CL2024001071A1 (es) 2021-10-11 2024-04-10 Métodos para efectuar un cambio hemodinámico administrando un anticuerpo anti-npr1.

Country Status (12)

Country Link
US (2) US20240327539A1 (https=)
EP (1) EP4415820A1 (https=)
JP (1) JP2024537284A (https=)
KR (1) KR20240099275A (https=)
CN (1) CN118159290A (https=)
AU (1) AU2022363841A1 (https=)
CA (1) CA3234238A1 (https=)
CL (1) CL2024001071A1 (https=)
CO (1) CO2024005662A2 (https=)
IL (1) IL311917A (https=)
MX (1) MX2024004302A (https=)
WO (1) WO2023064769A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL313265A (en) 2021-12-06 2024-08-01 Regeneron Pharma Antagonistic antibodies against NPR1 and methods of using them
WO2024251255A1 (zh) * 2023-06-08 2024-12-12 江苏恒瑞医药股份有限公司 抗npr1抗体及其医药用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US9090695B2 (en) 2008-12-03 2015-07-28 Morphosys Ag Antibodies for guanylyl cyclase receptors
MY205168A (en) 2018-10-23 2024-10-04 Regeneron Pharma Anti-npr1 antibodies and uses thereof
EA202193345A1 (ru) * 2019-06-12 2022-03-16 Новартис Аг Антитела к рецептору-1 натрийуретического пептида и способы их применения
US12325752B2 (en) * 2020-12-18 2025-06-10 Regeneron Pharmaceuticals, Inc. Immunoglobulin proteins that bind to NPR1 agonists

Also Published As

Publication number Publication date
WO2023064769A1 (en) 2023-04-20
AU2022363841A1 (en) 2024-03-28
US20240327539A1 (en) 2024-10-03
IL311917A (en) 2024-06-01
MX2024004302A (es) 2024-06-19
KR20240099275A (ko) 2024-06-28
CA3234238A1 (en) 2023-04-20
CO2024005662A2 (es) 2024-05-10
US20250034279A1 (en) 2025-01-30
EP4415820A1 (en) 2024-08-21
JP2024537284A (ja) 2024-10-10
CN118159290A (zh) 2024-06-07

Similar Documents

Publication Publication Date Title
CL2024001071A1 (es) Métodos para efectuar un cambio hemodinámico administrando un anticuerpo anti-npr1.
MX2020009856A (es) Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp).
MX2022004678A (es) Anticuerpo anti-beta amiloide para el tratamiento de la enfermedad de alzheimer.
BR112021019334A2 (pt) Anticorpos de cadeia pesada que se ligam ao psma
CO2021007613A2 (es) Formas cristalinas y formas de sal de un inhibidor de cinasa
CL2021003272A1 (es) Composición farmacéutica parenteral del agonista dual glp1/2
PE20220337A1 (es) Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos
MX2021008268A (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r.
CL2023003124A1 (es) Anticuerpos anti-tslp modificados
CL2024002623A1 (es) Formas solidas, sales y procesos de preparacion de un inhibidor de cdk2.
MX2023009882A (es) Anticuerpos anti-muc1-c y estructuras car-t.
MX2020011529A (es) Un metodo para optimizar la expresion de anticuerpos.
CR20230525A (es) Anticuerpos anti-cd20 y estructuras car-t
MX2023009874A (es) Anticuerpos anti-psma y estructuras car-t.
PE20151664A1 (es) Un polipeptido receptor del factor de crecimiento de fibroblasto soluble 3 (fgr3) para el uso en la prevencion o tratamiento de trastornos de retraso de crecimiento esqueletico
CO2025003362A2 (es) Conjugados de fármacos anticuerpo anti-sez6
BR112021020843A2 (pt) Conjunto de polipeptídeos precursores heterodiméricos, polipeptídeos heterodiméricos, métodos para gerar um polipeptídeo heterodimérico e para identificar um polipeptídeo heterodimérico multiespecífico, polipeptídeo heterodimérico multiespecífico, primeiro e segundo polipeptídeo precursor heterodimérico
MX2023000763A (es) Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrofilas.
CL2025000292A1 (es) Anticuerpos tmem219 y usos terapéuticos de los mismos
BR112023001471A2 (pt) Composição farmacêutica de anticorpo anti-pd-1 e uso da mesma
MX2022002941A (es) Cristal de derivado de 1,3,5-triazina o solvato del mismo y metodo para producir el mismo.
CO2024003094A2 (es) Compuesto imidazocíclico y aplicación del mismo
PE20221009A1 (es) Sintesis de un inhibidor de calicreina plasmatica a escala de proceso
MX2022006670A (es) Region fc de anticuerpo teniendo mayor afinidad de union al fcyriib.
MX2024011128A (es) Molecula de union a antigeno que se une especificamente a gprc5d y cd3 y su uso medico.